Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$123.10M+218.85%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Katherine A. Stueland
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 1,300
- Beta
- 1.99
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.28
Financials
Revenue
$123.10M+218.8%Net Income
$-12.33MEBITDA
$-3.63MFree Cash Flow
$-15.82MEPS (diluted)
$-0.41Shares Outstanding (diluted)
29.88M+431.0%Operating Expenses
$96.49MCash & Debt
$170.12MRevenue by Segment (annual)
$844.21MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $427.54M | $-21.02M | $-0.73 |
| 2024 | $305.45M | $-52.29M | $-1.94 |
| 2023 | $202.57M | $-175.77M | $-7.23 |
| 2022 | $234.69M | $-548.98M | $-53.63 |
| 2021 | $212.19M | $-245.39M | $-74.93 |
| 2020 | $179.32M | $-241.34M | $-33.16 |
| 2019 | $196.17M | $-29.70M | $-4.26 |
Valuation
WGShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (9)
- Newsseekingalpha.com·12d ago·Positive
GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript GeneDx Holdings Corp. ( WGS ) Q3 2026 Earnings Call November 9, 2026 4:30 PM EST Company Participants Sabrina Dunbar - Director of Investor Relations & Communications Katherine Stueland - CEO & Director Mark Gardner - President Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division David Westenberg - Piper Sandler & Co., Research Division Tycho Peterson - Jefferies LLC, Research…
View source ↗ - Newsseekingalpha.com·12d ago·Positive
GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability GeneDx Holdings is transitioning to sustained profitability, with strong revenue growth expected through 2027. WGS beat revenue estimates for Q3 but fell short on EPS estimates. Key strategies include optimizing reimbursement rates, operational efficiencies, and leveraging AI to enhance billing and payment reliability.
View source ↗ - Newsmarketbeat.com·13d ago·Neutral
GeneDx Q3 Earnings Call Highlights GeneDx NASDAQ: WGS reported third-quarter revenue of $123.1 million and raised its full-year profitability outlook, even as new documentation requirements led the genetic testing company to lower its expectations for test volume growth.
View source ↗ - Newszacks.com·13d ago·Positive
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.49 per share a year ago.
View source ↗ - Newsbusinesswire.com·30d ago·Neutral
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026 GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Tim…
View source ↗ - Newsdefenseworld.net·35d ago·Neutral
GeneDx (NASDAQ:WGS) Stock Falls 5.5% – Here’s What Happened Shares of GeneDx Holdings Corp. (NASDAQ: WGS - Get Free Report) were down 5.5% during mid-day trading on Friday. The company traded as low as $66.92 and last traded at $66.3710. Approximately 32,972 shares changed hands during trading, a decline of 96% from the average session volume of 919,692 shares. The stock had previously closed at
View source ↗ - Newsbusinesswire.com·51d ago·Neutral
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.
View source ↗ - Newszacks.com·95d ago·Neutral
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates? GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newsseekingalpha.com·96d ago·Neutral
GeneDx: Why I Think The Worst Is Behind The Business GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
View source ↗
Earnings
Mon, Feb 22(in 3 months)
Consensus estimate $0.40 per share
Typical surprise +90.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$0.28 vs $0.07beat
- Mon, Aug 3$0.01 vs $-0.19beat
- Mon, May 4$-0.28 vs $-0.06miss
- Mon, Feb 23$0.14 vs $0.11beat
- Tue, Oct 28$0.49 vs $0.28beat
- Tue, Jul 29$0.50 vs $0.10beat
Estimates and results for WGS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by WGS officers and directors.
- Bought
- $93.1m
- Sold
- $3.6m
27 trades
28 trades
- Stueland Katherinesold
- Stueland Katherinesold
- Stueland Katherinesold
- Stueland Katherinesold
- Stueland Katherinesold
- Feeley Kevinsold
- Feeley Kevinsold
- Feeley Kevinsold
45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in WGS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
